Clinical Trial

Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET

Name: Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET — clinical trial record (NCT07070648)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

This is a prospective, multicenter, multi-cohort study of ctDNA combined with PET for predicting the efficacy of standard first-line therapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

Trial Details

NCT Number	NCT07070648
Lead Sponsor	Fudan University
Conditions	Diffuse Large B-Cell Lymphoma, DLBCL
Enrollment	300 participants
Start Date	2025-05-09
Primary Completion	2026-12-30 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-07-17